We are live on ! Find out more
TRDA icon

Entrada Therapeutics
TRDA

52 hedge funds and large institutions have $361M invested in Entrada Therapeutics in 2023 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 24 increasing their positions, 6 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 6

125% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 4

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

11% more funds holding

Funds holding: 47 → 52 (+5)

8% more capital invested

Capital invested by funds: $334M → $361M (+$26.9M)

3.45% less ownership

Funds ownership: 78.69% → 75.24% (-3.4%)

Holders
52
Holders Change
+5
Holders Change %
+10.64%
% of All Funds
0.83%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.06%
New
9
Increased
24
Reduced
6
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Millennium Management
Millennium Management
New York
+$2.1M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.13M
3
Jane Street
Jane Street
New York
+$793K
4
CA
CHI Advisors
New York
+$753K
5
HF
HRT Financial
New York
+$513K

Top Sellers

1
Goldman Sachs
Goldman Sachs
New York
-$4.74M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$407K
3
RG
Redmile Group
California
-$300K
4
E
Ergoteles
New York
-$190K
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$164K
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$684K -$4.74M -354,863 -88%
Morgan Stanley
27
Morgan Stanley
New York
$606K +$225K +16,882 +68%
Qube Research & Technologies (QRT)
28
Qube Research & Technologies (QRT)
United Kingdom
$562K +$294K +22,000 +131%
HF
29
HRT Financial
New York
$556K +$513K +38,395 New
Bank of America
30
Bank of America
North Carolina
$490K +$380K +28,475 +538%
Northern Trust
31
Northern Trust
Illinois
$484K -$12.9K -967 -3%
N
32
Natixis
France
$444K +$66.8K +5,000 +19%
Swiss National Bank
33
Swiss National Bank
Switzerland
$344K -$37.4K -2,800 -11%
Marshall Wace
34
Marshall Wace
United Kingdom
$251K +$231K +17,327 New
LP
35
LMR Partners
United Kingdom
$189K +$174K +13,023 New
N
36
Nuveen
North Carolina
$188K +$173K +12,987 New
Bank of New York Mellon
37
Bank of New York Mellon
New York
$180K – – –
CS
38
Credit Suisse
Switzerland
$180K +$47.9K +3,588 +41%
Man Group
39
Man Group
United Kingdom
$163K – – –
6CM
40
683 Capital Management
New York
$150K – – –
Barclays
41
Barclays
United Kingdom
$148K -$7.26K -544 -5%
YIH
42
Y-Intercept (HK)
Hong Kong
$148K +$136K +10,188 New
California State Teachers Retirement System (CalSTRS)
43
California State Teachers Retirement System (CalSTRS)
California
$140K +$1.56K +117 +1%
JP Morgan Chase
44
JP Morgan Chase
New York
$124K +$12.6K +947 +12%
CSS
45
Cubist Systematic Strategies
Connecticut
$60.3K +$50.1K +3,755 +927%
Legal & General Group
46
Legal & General Group
United Kingdom
$51.8K +$8.51K +637 +22%
PMEF
47
Point72 Middle East FZE
United Arab Emirates
$49.9K +$45.9K +3,441 New
Point72 Asset Management
48
Point72 Asset Management
Connecticut
$41.2K +$37.9K +2,840 New
UBS Group
49
UBS Group
Switzerland
$21.1K +$2.67K +200 +16%
TRCT
50
Tower Research Capital (TRC)
New York
$19K +$11.3K +845 +189%
1
2
3

TRDA Hedge Fund Activity: Q1 2023 in Review

52 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Entrada Therapeutics (TRDA) for Q1 2023, worth a combined $361M — up 8% from $334M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new TRDA positions and 4 closed out — a net gain of 5 holders — while 24 added to existing stakes and 6 trimmed.

The largest buyer was Millennium Management, adding an estimated $2.1M. The largest seller was Goldman Sachs, cutting an estimated $4.74M.

  • 52 institutional investors held Entrada Therapeutics (TRDA) as of Q1 2023, up from 47 in Q4 2022.
  • Funds reported $361M of Entrada Therapeutics stock for Q1 2023, up 8% quarter-over-quarter.
  • 9 funds opened new Entrada Therapeutics positions in Q1 2023 and 4 closed out, a net change of +5 holders.
  • The largest Entrada Therapeutics buyer in Q1 2023 was Millennium Management, an estimated $2.1M added.
  • The largest Entrada Therapeutics seller in Q1 2023 was Goldman Sachs, an estimated $4.74M sold.

Based on aggregated 13F filings for Q1 2023.